S. Loibl et al.
Annals of Oncology
52. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal
testing and incidental detection of occult maternal malignancies.
JAMA. 2015;314(2):162-169.
53. Lenaerts L, Brison N, Maggen C, et al. Comprehensive genome-wide
analysis of routine non-invasive test data allows cancer prediction: a
single-center retrospective analysis of over 85,000 pregnancies.
EClinicalMedicine. 2021;35:100856.
54. Lenaerts L, Van Calsteren K, Che H, et al. Pregnant women with
confirmed neoplasms should not have noninvasive prenatal testing.
Prenat Diagn. 2019;39(12):1162-1165.
55. van Gerwen M, Maggen C, Cardonick E, et al. Association of
chemotherapy timing in pregnancy with congenital malformation.
JAMA Netw Open. 2021;4(6):e2113180.
56. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer
during pregnancy: an observational study. Lancet Oncol. 2012;13(9):
887-896.
57. Wolters V, Heimovaara J, Maggen C, et al. Management of pregnancy
in women with cancer. Int J Gynecol Cancer. 2021;31(3):314-322.
58. Van Calsteren K, Verbesselt R, Ottevanger N, et al. Pharmacokinetics
of chemotherapeutic agents in pregnancy: a preclinical and clinical
study. Acta Obstet Gynecol Scand. 2010;89(10):1338-1345.
59. Damoiseaux D, Calpe S, Rosing H, et al. Presence of five chemo-
therapeutic drugs in breast milk as a guide for the safe use of
chemotherapy during breastfeeding: results from a case series. Clin
Pharmacol Ther. 2022;112(2):404-410.
60. Loibl S, Han S, Mayer K, et al. Neoadjuvant chemotherapy for patients
with breast cancer during pregnancy (BCP). J Clin Oncol.
2014;32(suppl 15):1071.
61. Rouzier R, Werkoff G, Uzan C, et al. Pregnancy-associated breast
cancer is as chemosensitive as non-pregnancy-associated breast
cancer in the neoadjuvant setting. Ann Oncol. 2011;22(7):1582-
1587.
62. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated
breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-
year efficacy and late normal tissue effects results from a multi-
centre, non-inferiority, randomised, phase 3 trial. Lancet.
2020;395(10237):1613-1626.
63. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy
in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging.
2010;37(1):78-83.
64. Han SN, Amant F, Cardonick EH, et al. Axillary staging for breast
cancer during pregnancy: feasibility and safety of sentinel lymph
node biopsy. Breast Cancer Res Treat. 2018;168(2):551-557.
65. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the
programmed death ligand 1 in fetomaternal tolerance. J Exp Med.
2005;202(2):231-237.
66. Pentsuk N, van der Laan JW. An interspecies comparison of placental
antibody transfer: new insights into developmental toxicity testing of
monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol.
2009;86(4):328-344.
67. Andrikopoulou A, Korakiti AM, Apostolidou K, et al. Immune check-
point inhibitor administration during pregnancy: a case series. ESMO
Open. 2021;6(5):100262.
68. Burotto M, Gormaz JG, Samtani S, et al. Viable pregnancy in a patient
with metastatic melanoma treated with double checkpoint immu-
notherapy. Semin Oncol. 2018;45(3):164-169.
69. Mehta A, Kim KB, Minor DR. Case report of a pregnancy during Ipi-
limumab therapy. J Glob Oncol. 2018;4:1-3.
70. Borgers JSW, Heimovaara JH, Cardonick E, et al. Immunotherapy for
cancer treatment during pregnancy. Lancet Oncol. 2021;22(12):e550-
e561.
71. de Haan J, Verheecke M, Van Calsteren K, et al. Oncological man-
agement and obstetric and neonatal outcomes for women diagnosed
with cancer during pregnancy: a 20-year international cohort study of
1170 patients. Lancet Oncol. 2018;19(3):337-346.
72. Jiang X, Ye Z, Yu W, et al. Chemotherapy for ovarian cancer during
pregnancy: a systematic review and meta-analysis of case reports and
series. J Obstet Gynaecol Res. 2021;47(10):3425-3436.
Volume xxx - Issue xxx - 2023
73. Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer
of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a
baboon model. Gynecol Oncol. 2010;119(3):594-600.
74. Geijteman ECT, Wensveen CWM, Duvekot JJ, et al. A child with severe
hearing loss associated with maternal cisplatin treatment during
pregnancy. Obstet Gynecol. 2014;124(2 Pt 2 suppl 1):454-456.
75. Schmid P, Cortes J, Dent R, et al. Event-free survival with pem-
brolizumab in early triple-negative breast cancer. N Engl J Med.
2022;386(6):556-567.
76. Schmid P, Dent R, O’Shaughnessy J. Pembrolizumab for early triple-
negative breast cancer. reply. N Engl J Med. 2020;382(26):e108.
77. Winship AL, Alesi LR, Sant S, et al. Checkpoint inhibitor immuno-
therapy diminishes oocyte number and quality in mice. Nat Cancer.
2022;3(8):1-13.
78. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during
pregnancy: adapting recent advances in breast cancer care for
pregnant patients. JAMA Oncol. 2015;1(8):1145-1153.
79. Yamasaki K, Noda S, Muroi T, et al. Effects of in utero and lacta-
tional exposure to tamoxifen in SD rats. Toxicol Lett. 2005;156(2):
289-296.
80. Buonomo B, Brunello A, Noli S, et al. Tamoxifen exposure during
pregnancy: a systematic review and three more cases. Breast Care
(Basel). 2020;15(2):148-156.
81. Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of
advanced breast cancer during pregnancy–case report and literature
review. Gynecol Oncol. 2001;80(3):405-408.
82. Joshi A, Mahfooz S, Maurya VK, et al. PARP1 during embryo im-
plantation and its upregulation by oestradiol in mice. Reproduction.
2014;147(6):765-780.
83. Kelleher AM, Setlem R, Dantzer F, et al. Deficiency of PARP-1 and
PARP-2 in the mouse uterus results in decidualization failure
and pregnancy loss. Proc Natl Acad Sci U S A. 2021;118(40):
e2109252118.
84. James AD, Schiller H, Marvalin C, et al. An integrated assessment of
the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing
preclinical in vitro, in vivo, and human ADME data. Pharmacol Res
Perspect. 2020;8(3):e00599.
85. Lambertini M, Peccatori FA, Azim HA Jr. Targeted agents for cancer
treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301-309.
86. Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during preg-
nancy with monoclonal antibodies: a real challenge. Expert Rev Clin
Immunol. 2010;6(6):821-826.
87. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab
after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J
Med. 2005;353(16):1659-1672.
88. Calhoun DA, Rosa C, Christensen RD. Transplacental passage of re-
combinant human granulocyte colony-stimulating factor in women
with an imminent preterm delivery. Am J Obstet Gynecol.
1996;174(4):1306-1311.
89. Gregor H, Egarter C, Levin D, et al. The passage of granulocyte-
macrophage colony-stimulating factor across the human placenta
perfused in vitro. J Soc Gynecol Investig. 1999;6(6):307-310.
90. Berends C, Maggen C, Lok CAR, et al. Maternal and neonatal outcome
after the use of G-CSF for cancer treatment during pregnancy. Can-
cers (Basel). 2021;13(6):1214.
91. Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal out-
comes of dose-dense chemotherapy for breast cancer in pregnancy.
Obstet Gynecol. 2012;120(6):1267-1272.
92. Cardonick E, Irfan F, Torres N. The use of neupogen (filgrastim) or
neulasta (pegfilgrastim) during pregnancy when chemotherapy is
indicated for maternal cancer treatment. J Cancer Ther. 2012;3(2):
157-161.
93. Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-
stimulating factor during pregnancy in women with chronic neu-
tropenia. Obstet Gynecol. 2015;125(1):197-203.
94. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing
neonatal infections. Cochrane Database Syst Rev. 2003;2003(3):
CD003066.
https://doi.org/10.1016/j.annonc.2023.08.001 17